Novo Nordisk announced it will spend $1.46 billion to discover, develop and commercialize molecular glue degraders from San Diego-based biotech Neomorph. Per terms of the deal, the Danish pharma giant will provide Neomorph with an upfront payment as well as near-term milestone payments in addition to funding for research and development. (MM+M)

Ruth Gottesman, the 93-year-old widow of a Wall Street financier, donated $1 billion to Bronx-based Albert Einstein College of Medicine to provide free tuition in perpetuity. The donation is notable not only for its staggering size, but also because it is going to a medical institution in the Bronx, the city’s poorest borough. (The New York Times)

Zealand Pharma posted strong results from a trial of a liver disease treatment that has been touted as a potential competitor in the booming weight loss drug market. The Phase 2 trial of the survodutide drug showed 83% of adults saw positive results for a form of liver inflammation caused by excess fat cells known as “MASH.” (CNBC)

GSK announced positive headline results from a pivotal late-stage trial of its gonorrhoea drug, gepotidacin. The EAGLE-1 phase III trial met its primary efficacy endpoint of non-inferiority comparing gepotidacin with intramuscular ceftriaxone plus oral azithromycin combination therapy. (Seeking Alpha)

BeiGene said its four-target natural killer cell therapy collaboration with Shoreline Biosciences is over. BeiGene terminated the pact earlier this year. The biotech initially invested $45 million upfront in January 2022, after the partners disclosed the agreement in June 2021. (Endpoints News)

Click here to view yesterday’s Five things for pharma marketers to know.